Enrolling By Invitation PHASE1 INTERVENTIONAL 2-arm
NCT07178327
Phase I Clinical Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of LYN101
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Administration of LYN101 in Healthy Subjects and Multiple Administrations in Postmenopausal Women With Low Bone Mass
Sponsor: Shanghai TTM-Bio Technology Co., Ltd
Conditions
Osteoporotic Fracture
Updated 1 time since 2025 Last updated: Sep 16, 2025 Started: Sep 6, 2025 Primary completion: Sep 6, 2026 Completion: Sep 6, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07178327, this PHASE1 trial focuses on Osteoporotic Fracture and remains ongoing. Sponsored by Shanghai TTM-Bio Technology Co., Ltd, it has been updated 1 time since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Enrolling By Invitation — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Shanghai TTM-Bio Technology Co., Ltd
Data source: Shanghai TTM-Bio Technology Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .